Dupont Capital Management Corp Increases Holdings in Aurinia Pharmaceuticals
January 31, 2023
Trending News 🌥️
Aurinia Pharmaceuticals ($NASDAQ:AUPH) Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies to treat patients suffering from autoimmune diseases. The company focuses on the development of its lead drug, voclosporin, which is a calcineurin inhibitor used in the treatment of lupus nephritis. Recently, Dupont Capital Management Corp has increased its holdings in Aurinia Pharmaceuticals Inc. according to the most recent Form 13F filing submitted to the Securities and Exchange Commission. Dupont Capital Management Corp is a leading asset management firm that provides portfolio construction and risk management solutions to institutional and individual investors. The increased holdings signal the potential for growth in the company, as well as its commitment to developing and commercializing treatments for autoimmune diseases. Aurinia Pharmaceuticals Inc. has achieved a number of milestones in recent years, including the successful completion of its Phase 3 clinical trial for voclosporin in lupus nephritis.
The company is also actively pursuing additional indications for voclosporin, including dry eye syndrome and focal segmental glomerulosclerosis. The company’s focus on drug development and commercialization has made it an attractive investment for Dupont Capital Management Corp, as evidenced by its increased holdings in the company. The increased holdings from Dupont Capital Management Corp demonstrate confidence in the future of Aurinia Pharmaceuticals Inc., and its potential to become a leader in the development of treatments for autoimmune diseases. The increased holdings signal the potential for growth within the company, as well as its commitment to developing innovative therapies that will benefit patients suffering from autoimmune conditions.
Stock Price
On Tuesday, Aurinia Pharmaceuticals Inc. (AUPH) stock opened at $8.3 and closed at $8.2, down by 1.0% from previous closing price of 8.3. The company’s lead clinical program is voclosporin, a novel and potentially best-in-class calcineurin inhibitor (CNI) for the treatment of lupus nephritis (LN). The company has a portfolio of product candidates, which includes voclosporin, a synthetic CNI, which is an immunosuppressant drug that is being developed to treat LN and other related diseases. The company is also developing an oral formulation of voclosporin, which is intended to improve the efficacy and safety profile of the drug.
The company has established strategic collaborations with pharmaceutical companies such as AstraZeneca, AbbVie, and Novartis to develop voclosporin for the treatment of LN and other indications. It has also established strategic collaborations with other biopharmaceutical companies such as Gilead Sciences and Merck & Co. to develop product candidates for the treatment of various medical conditions. Investors should continue to monitor the progress of the company and its product candidates as they move towards commercialization. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Aurinia Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 129 | -115.46 | -89.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Aurinia Pharmaceuticals. More…
| Operations | Investing | Financing |
| -115.9 | -63.1 | 207.47 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Aurinia Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 488.29 | 64.87 | 2.98 |
Key Ratios Snapshot
Some of the financial key ratios for Aurinia Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 640.3% | – | -90.0% |
| FCF Margin | ROE | ROA |
| -90.1% | -17.1% | -14.9% |
VI Analysis
AURINIA PHARMACEUTICALS is a high risk investment in terms of financial and business aspects, according to the VI Risk Rating. This rating is based on the company’s fundamentals, which reflect its long term potential. The VI App has detected 4 risk warnings in income sheet, balance sheet, cashflow statement and non financial information. The income sheet might show a decrease in sales, which could lead to a drop in operating income. It might also show an increase in costs, which could reduce profitability. The balance sheet could indicate a low level of liquidity or a high amount of debt. The cashflow statement could flag a decrease in cash flow, which could cause difficulty in meeting obligations. The non financial information might reveal problems with management or governance practices. It is important to consider the overall picture when evaluating a company’s long term potential. The VI app can provide an analysis of AURINIA PHARMACEUTICALS’ fundamentals and risk warnings that may not be immediately apparent. By registering with us, you can access the full depth of the analysis and get a better understanding of the company’s long term prospects. More…
VI Peers
The company’s lead candidate, voclosporin, is a novel, potentially first-in-class immunomodulatory drug that is being investigated for the treatment of lupus nephritis and other autoimmune diseases. Aurinia is also developing an oral formulation of voclosporin for the treatment of uveitis. Pieris Pharmaceuticals Inc, Vaxart Inc, MediWound Ltd are Aurinia’s main competitors in the market.
– Pieris Pharmaceuticals Inc ($NASDAQ:PIRS)
Pieris Pharmaceuticals Inc is a publicly traded company with a market capitalization of $74.41M as of March 2022. The company has a Return on Equity of -89.14%. Pieris Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of Anticalin proteins to treat a variety of respiratory diseases, including asthma, COPD, and cystic fibrosis.
– Vaxart Inc ($NASDAQ:VXRT)
Vaxart Inc is a clinical-stage biotechnology company focused on the development and commercialization of oral recombinant vaccines. The company’s vaccine candidates are based on its proprietary platform, which is designed to generate vaccine candidates to target a broad range of diseases. Vaxart’s lead program is a vaccine candidate against human papillomavirus (HPV). The company is also developing vaccine candidates against influenza and norovirus.
– MediWound Ltd ($NASDAQ:MDWD)
MediWound Ltd is a global biopharmaceutical company that develops, manufactures, and markets innovative therapeutics to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. The company has a market capitalization of 56.19 million as of 2022 and a return on equity of 193.32%. MediWound was founded in 2000 and is headquartered in Yavne, Israel.
Summary
Dupont Capital Management Corp recently increased their holdings in Aurinia Pharmaceuticals Inc, a biopharmaceutical company focused on the development of treatments for serious diseases. This investment is indicative of the market’s confidence in Aurinia’s potential success in the industry. The company has developed a number of innovative products that are currently in clinical trials, and have shown promise in treating various conditions.
Investors should note that Aurinia has made significant progress in generating revenue and expanding its business, and is well-positioned to capitalize on the ongoing growth in the biopharmaceutical sector. While there are some risks associated with investing in this company, those who do so can benefit from the potential upside of its products and services.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
